Dr. Catherine Morris -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Catherine Morris, a Internal Medicine physician based in City, SC. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Catherine Morris has received $4,972.84 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Catherine Morris
- Medical Specialty: Internal Medicine
- Practice Location: City, SC, South Carolina
- NPI Number: 1650358064
- Transparency Score: 50/100
- Payment Records Span: 2026-03-25 to 2026-03-25
Payment Summary
Dr. Catherine Morris has received a total of $4,972.84 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $4,972.84 per transaction.
- Total Payments Received: $4,972.84
- Number of Transactions: 1
- Average Payment: $4,972.84
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Internal Medicine. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
Payment Breakdown by Category
The following table shows how Dr. Catherine Morris's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Travel & Lodging | $4,972.84 | Transportation and hotel expenses for conferences and meetings |
The largest payment category for Dr. Catherine Morris is Travel & Lodging, accounting for 100% ($4,972.84) of total pharmaceutical payments received. This represents the primary type of financial relationship between Dr. Catherine Morris and pharmaceutical companies.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Catherine Morris. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Pfizer Inc | $4,972.84 | 1 |
Dr. Catherine Morris has a financial relationship with Pfizer Inc, receiving $4,972.84 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Catherine Morris's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Dr. Catherine Morris, an Internal Medicine physician in City, SC, has a pharmaceutical payment profile characterized by a single, notable transaction. With a total of $4,972.84 in reported payments from pharmaceutical companies, Dr. Morris's financial interactions with the industry are minimal compared to the broader landscape of Internal Medicine. The sole payment received originates from Pfizer Inc., amounting to the full $4,972.84, and is categorized as travel, with a future date of March 25, 2026. This singular event, while specific, does not represent a pattern of extensive financial engagement. In the context of Internal Medicine, where physicians may engage in various forms of collaboration with pharmaceutical companies, such as research, consulting, or speaking engagements, Dr. Morris's profile stands out for its simplicity. The absence of recurring payments, diverse company affiliations, or varied payment types suggests a limited scope of interaction. The payment's classification as 'travel' for a future date is also noteworthy. While travel payments can cover legitimate expenses related to professional development or conferences, a single, substantial travel payment warrants understanding the purpose and context. For patients, this profile indicates a doctor with very limited reported financial ties to the pharmaceutical industry. The single payment, while specific, does not inherently suggest bias in clinical decision-making. However, it is always prudent for patients to maintain open communication with their healthcare providers about any potential influences on care. Understanding the nature of such payments, even when infrequent, allows for a more informed patient-doctor relationship. The transparency provided by reporting mechanisms like CMS Open Payments is designed to empower patients with information, fostering trust and informed decision-making regarding their healthcare.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Catherine Morris is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
When considering your doctor's relationship with pharmaceutical companies, it's helpful to remember that not all payments are inherently problematic. Many involve legitimate professional activities like research, education, or consulting that can benefit patient care by advancing medical knowledge. However, it's wise to be informed. At your next appointment, you might consider asking your doctor about their involvement with pharmaceutical companies, if you feel comfortable doing so. You could inquire if they attend industry-sponsored educational events or participate in research. Pay attention to whether your doctor seems overly enthusiastic about a particular drug or dismissive of alternatives without clear clinical justification. Red flags might include a doctor consistently prescribing newer, more expensive medications when older, equally effective, and cheaper options exist, especially if they have a strong financial tie to the manufacturer of that specific drug. It's important to evaluate your doctor's prescribing patterns based on evidence-based guidelines and your individual health needs. If you have concerns, discuss them openly. A doctor who is transparent about their relationships and can explain their prescribing choices based on patient benefit is generally a positive sign. Remember, the goal is to ensure your treatment plan is centered on your well-being, not influenced by external financial incentives.
Peer Comparison: How Dr. Catherine Morris Compares to Other Internal Medicine Physicians
Dr. Morris's total pharmaceutical payments of $4,972.84 are significantly lower than the average for Internal Medicine physicians. While averages can vary widely, many Internal Medicine doctors receive multiple payments throughout the year for various activities, often totaling several thousand dollars annually. Dr. Morris's profile, with a single payment, places her well below the typical engagement level seen within her specialty.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Catherine Morris in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Pfizer Inc | $4,972.84 | travel | N/A | 2026-03-25 | Not Assessed |
Frequently Asked Questions About Dr. Catherine Morris's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
Is Dr. Catherine Morris taking too much pharma money?
Dr. Catherine Morris has received a total of $4,972.84 in pharmaceutical payments, stemming from a single transaction with Pfizer Inc. This amount is considerably lower than the average for Internal Medicine physicians, who often receive multiple payments for various professional activities. Given the minimal and singular nature of these payments, it does not suggest an excessive financial relationship with the pharmaceutical industry.
What pharma companies pay Dr. Catherine Morris?
Dr. Catherine Morris receives payments exclusively from Pfizer Inc., totaling $4,972.84. This represents her entire reported pharmaceutical payment history.
Should I switch doctors because of pharma payments?
Switching doctors solely based on a doctor's pharmaceutical payment history is generally not recommended unless there are clear indications of compromised care. Dr. Morris's payment profile is minimal. Focus on your doctor's overall quality of care, communication, and whether you trust their clinical judgment. If you have specific concerns about their prescribing habits or transparency, discuss them directly.
What kinds of payments does this doctor receive?
Dr. Morris has received one payment categorized as 'travel' from Pfizer Inc., amounting to $4,972.84. This is the only type of payment reported in her profile, indicating no reported income from consulting, speaking, research, meals, or ownership interests.
How do these payments compare to other Internal Medicine?
Dr. Morris's total payment of $4,972.84 is significantly lower than the average for Internal Medicine physicians. Many physicians in this specialty engage in more frequent and varied financial relationships with pharmaceutical companies, resulting in higher overall payment volumes.
Do pharma payments affect prescribing quality?
Research suggests that even small payments can influence prescribing habits, potentially leading to increased use of the paying company's drugs. However, the impact varies greatly depending on the type and amount of payment, as well as the individual physician. Dr. Morris's limited payment history makes it difficult to draw conclusions about its effect on her prescribing quality.
How can I verify this payment data?
You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. Visit the official CMS Open Payments website and search for Dr. Catherine Morris using her NPI number (1650358064) or her name and location. This will provide access to the detailed records of payments made to healthcare providers.
Understanding This Doctor Payment Report
This transparency report for Dr. Catherine Morris is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Internal Medicine physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Catherine Morris's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Catherine Morris and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Internal Medicine Specialty Payment Data -- See payment patterns for all internal medicine physicians
- South Carolina Physician Payments -- Browse pharmaceutical payments to physicians in South Carolina
- Internal Medicine Physicians in South Carolina -- Compare Dr. Catherine Morris to peers in the same state and specialty
- Pfizer Inc Payment Profile -- View all payments made by Dr. Catherine Morris's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Catherine Morris's NPI (1650358064) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.